-
1 Comment
Roche Holding AG is currently in a long term uptrend where the price is trading 12.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
Finally, its free cash flow fell by 32.8% to $5B since the same quarter in the previous year.
Based on the above factors, Roche Holding AG gets an overall score of 2/5.
Sector | Healthcare |
---|---|
Industry | Drug Manufacturers - General |
ISIN | US7711951043 |
Exchange | F |
CurrencyCode | EUR |
Market Cap | 234B |
---|---|
PE Ratio | 26.05 |
Target Price | 52.44 |
Dividend Yield | 3.5% |
Beta | 0.22 |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for RHO6.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025